##SAMPLE=<ID=Normal2,IsTumor=no>
##SAMPLE=<ID=Tumor2,IsTumor=yes>
##ANALYSISTYPE=SOMATIC_PAIR
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample Tumor2).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample Tumor2).
##DESCRIPTION=normal_af=Mutant allele frequency in normal (Sample Normal2).
##DESCRIPTION=normal_dp=Normal depth (Sample Normal2).
##DESCRIPTION=filter=Filter criteria from vcf file.
##DESCRIPTION=snp_q=Quality parameters - SNP quality (QUAL).
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon number, HGVS.c, HGVS.p).
##DESCRIPTION=interpro=Interpro domains.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in all populations of 1000g project.
##DESCRIPTION=ExAC=Allele frequency in all populations of ExAC project.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD database.
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=MetaLR=MetaLR effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=Sift=Sift effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen2=Polyphen2 (HVAR) effect prediction: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=FATHMM=FATHMM effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 15-20.
##DESCRIPTION=ihdb_hom=Homozygous variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_het=Heterozyous variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_wt=Wildtype variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_allsys_hom=Homozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=ihdb_allsys_het=Heterozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validated=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Comments from the NGSD. Comments of other samples are listed in brackets!
##DESCRIPTION=gene_info=General gene information from the NGSD.
##DESCRIPTION=som_ihdb_c=Somatic variant count within NGSD.
##DESCRIPTION=som_ihdb_p=Projects with somatic variant in NGSD.
##FILTER=all-unknown=Allele unknown (filter_vcf).
##FILTER=depth-nor=Sequencing depth normal is too low < 20 (filter_vcf).
##FILTER=depth-tum=Sequencing depth tumor is too low < 20 (filter_vcf).
##FILTER=freq-nor=Allele frequencies in tumor < 0.05 or allele frequencies in normal > 0.01 (filter_vcf).
##FILTER=freq-tum=Allele frequencies in tumor < 0.05 or allele frequencies in normal > 0.01 (filter_vcf).
##FILTER=lt-3-reads=Less than 3 supporting tumor reads (filter_vcf).
##FILTER=not-cod-spli=Not a coding or splicing variant (filter_vcf).
##FILTER=off-target=Variant outside the panel/exome target region.
##FILTER=special_chromosome=Special chromosome.
##FILTER=syn-var=Synonymous variant (filter_vcf).
#chr	start	end	ref	obs	tumor_af	tumor_dp	normal_af	normal_dp	filter	snp_q	gene	variant_type	coding_and_splicing	interpro	Pathway_KEGG_full	Function_description	Pathway_BioCarta_full	RepeatMasker	dbSNP	1000g	ExAC	gnomAD	COSMIC	OMIM	ClinVar	HGMD	phyloP	MetaLR	Sift	PolyPhen2	FATHMM	CADD	ihdb_hom	ihdb_het	ihdb_wt	ihdb_allsys_hom	ihdb_allsys_het	classification	classification_comment	validated	comment	gene_info	som_ihdb_c	som_ihdb_p
chr1	98157181	98157181	C	T	0.4788	354	0.0000	358	not-cod-spli;off-target	684	DPYD	intron_variant,non_coding_transcript_exon_variant	DPYD:ENST00000370192:intron_variant:MODIFIER:exon7/22:c.762+92G>A:,DPYD:ENST00000474241:non_coding_transcript_exon_variant:MODIFIER:exon4/4:n.618G>A:		Pyrimidine metabolism;beta-Alanine metabolism;Pantothenate and CoA biosynthesis;Drug metabolism - other enzymes	Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil				0.0000	0.0000	0.0000		612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270|5-fluorouracil toxicity,274270];												0	0					DPYD (inh=AR pLI=0.00)	1	SomaticAndTreatment,
chr1	98164716	98164716	A	C	0.4500	20	0.0000	27	not-cod-spli;off-target	64	DPYD	intron_variant	DPYD:ENST00000370192:intron_variant:MODIFIER:exon6/22:c.680+191T>G:,DPYD:ENST00000474241:intron_variant:MODIFIER:exon3/3:n.444+191T>G:,DPYD:ENST00000423006:intron_variant:MODIFIER:exon6/6:c.*211+191T>G:		Pyrimidine metabolism;beta-Alanine metabolism;Pantothenate and CoA biosynthesis;Drug metabolism - other enzymes	Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil				0.0000	0.0000	0.0000		612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270|5-fluorouracil toxicity,274270];												0	0					DPYD (inh=AR pLI=0.00)	1	SomaticAndTreatment,
chr1	98165813	98165813	G	A	0.4141	723	0.0000	690	off-target	1093	DPYD	stop_gained,intron_variant	DPYD:ENST00000423006:stop_gained:HIGH:exon5/7:c.418C>T:p.Gln140*,DPYD:ENST00000370192:intron_variant:MODIFIER:exon5/22:c.484-710C>T:,DPYD:ENST00000474241:intron_variant:MODIFIER:exon2/3:n.248-710C>T:		Pyrimidine metabolism;beta-Alanine metabolism;Pantothenate and CoA biosynthesis;Drug metabolism - other enzymes	Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil				0.0000	0.0000	0.0000		612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270|5-fluorouracil toxicity,274270];			0.064000					1.48				0	0					DPYD (inh=AR pLI=0.00)	1	SomaticAndTreatment,
chr1	115256528	115256528	T	C	0.4271	782	0.0012	836	syn-var	1278	NRAS	synonymous_variant	NRAS:ENST00000369535:synonymous_variant:LOW:exon3/7:c.183A>G:p.Gln61Gln		MAPK signaling pathway;ErbB signaling pathway;Axon guidance;VEGF signaling pathway;Tight junction;Gap junction;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;B cell receptor signaling pathway;Fc epsilon RI signaling pathway;Long-term potentiation;Long-term depression;Regulation of actin cytoskeleton;Insulin signaling pathway;GnRH signaling pathway;Melanogenesis;Renal cell carcinoma;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Non-small cell lung cancer	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity				0.0000	0.0000	0.0000	COSM587	164790 [NRAS (confirmed) RAS-associated autoimmune lymphoproliferative syndrome type IV,somatic,614470|Noonan syndrome 6,613224|Epidermal nevus,somatic,162900|Thyroid carcinoma,follicular,somatic,188470|Colorectal cancer,somatic,114500|Melanocytic nevus syndrome,congenital,somatic,137550|Neurocutaneous melanosis,somatic,249400|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200];												0	0					NRAS (inh=AD pLI=0.91)	2	SomaticAndTreatment,TEST_SomaticAndTreatment,
chr1	115256530	115256530	G	T	0.4299	771	0.0000	827		1302	NRAS	missense_variant	NRAS:ENST00000369535:missense_variant:MODERATE:exon3/7:c.181C>A:p.Gln61Lys	Small_GTP-binding_protein_domain__1_	MAPK signaling pathway;ErbB signaling pathway;Axon guidance;VEGF signaling pathway;Tight junction;Gap junction;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;B cell receptor signaling pathway;Fc epsilon RI signaling pathway;Long-term potentiation;Long-term depression;Regulation of actin cytoskeleton;Insulin signaling pathway;GnRH signaling pathway;Melanogenesis;Renal cell carcinoma;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Non-small cell lung cancer	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity			rs121913254	0.0000	0.0000	0.00000	COSM580	164790 [NRAS (confirmed) RAS-associated autoimmune lymphoproliferative syndrome type IV,somatic,614470|Noonan syndrome 6,613224|Epidermal nevus,somatic,162900|Thyroid carcinoma,follicular,somatic,188470|Colorectal cancer,somatic,114500|Melanocytic nevus syndrome,congenital,somatic,137550|Neurocutaneous melanosis,somatic,249400|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200];	RCV000114746.5 [pathogenic]; RCV000144964.3 [pathogenic]; 		9.520000	D	D	P	D	24.10				0	0		[import GPD] Christopher Schroeder 2013-09-09 11:18:14 -type: lit / general -link: http://jco.ascopubs.org/content/31/26/3173?cmpid=jco_etoc_10September2013 -doi: 10.1200/JCO.2013.50.3144 -drugs: imatinib Another Option in Our KIT of Effective Therapies for Advanced Melanoma => Of 24 evaluable patients, seven achieved a partial response (PR) to therapy, with five patients' responses confirmed on subsequent imaging studies, for an overall confirmed response rate (RR) of 21%. This clinical activity is similar to that observed in two other trials of imatinib in patients with melanoma molecularly selected for the presence of KIT alterations. Our group3 screened 295 patients for KIT mutations or amplification, identified 51 patients with such alterations, treated 25 evaluable patients, and observed a confirmed RR of 16%, with responses durable for longer than 1 year. Guo et al4 screened 501 patients for KIT mutations or amplification, treated 43 patients with imatinib, and observed an RR of 23.3%. The significance of the responses observed on these three trials is most evident when placed in the context of three prior negative phase II trials of imatinib in molecularly unselected melanoma patients initiated before the identification of KIT mutations in this disease, in which only one radiographic response was observed in 62 patients treated across the three trials.5â€“7  => Although approximately 70% of KIT mutations identified in melanoma affect the juxtamembrane domain (exon 11, most commonly L576P) and the proximal kinase domain (exon 13, most commonly K642E), others have been identified that likely represent passenger mutations of no biologic significance.  => NRAS Q61K mutation plus a previously detected W557G KIT mutation was also identified in a secondarily resistant tumor after a 7-month course of sunitinib, suggesting that NRAS mutations may also be a mechanism of secondary resistance to KIT inhibition.12,14			NRAS (inh=AD pLI=0.91)	9	Leuk,Ringversuch_EMQN,SomaticAndTreatment,TEST_SomaticAndTreatment,
chr1	120056552	120056552	G	A	0.4286	533	0.0000	622		962	HSD3B1	missense_variant	HSD3B1:ENST00000235547:missense_variant:MODERATE:exon4/4:c.412G>A:p.Glu138Lys,HSD3B1:ENST00000369413:missense_variant:MODERATE:exon4/4:c.406G>A:p.Glu136Lys,HSD3B1:ENST00000528909:missense_variant:MODERATE:exon3/3:c.406G>A:p.Glu136Lys	3-beta_hydroxysteroid_dehydrogenase/isomerase__1_,NAD_P_-binding_domain__1_	C21-Steroid hormone metabolism;Androgen and estrogen metabolism	3-beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. The 3-beta-HSD enzymatic system plays a crucial role in the biosynthesis of all classes of hormonal steroids. Efficiently catalyzes the transformation of pregnenolone to progesterone, 17-alpha-hydroxypregnenolone to 17- alpha-hydroxyprogesterone, DHEA to 4-androstenedione, dihydrotestosterone to 5-alpha-androstane-3 beta,17 beta-diol, dehydroepiandrosterone to androstenedione and 5-alpha-androstan-3 beta,17 beta-diol to 5-alpha-dihydrotestosterone				0.0000	0.0000	0.0000	COSM3862388				4.806000	T	T,T,T	B,B	D,D,D	11.43				0	0					HSD3B1 (inh=n/a pLI=0.00)	2	SomaticAndTreatment,TEST_SomaticAndTreatment,
